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ProfileBiopolis: Village on a HillSince the opening of Biopolis in 2003,
Singapore’s 18 acre science complex
on a hill has attracted the rest of the
world’s curiosity.
What’s going on at Centros, Helios,
Nanos, and Genome, to name only
four of Biopolis’s nine geometrically
eye-catching buildings (Figure 1)?
They leave the impression of stepping
into the future, which is right in sync
with a larger plan orchestrated by the
industrial engineer Philip Yeo. Yeo,
chairman first of the Economic Devel-
opment Board and later of Singapore’s
A*STAR science agency, saw the need
to stimulate Singapore’s economy,
which, by 2001, was experiencing its
steepest downturn since its indepen-
dence, with an ambitious Biomedical
Sciences Initiative.
If all goes according to plan, be-
tween 2000 and 2010, the government
will have spent roughly 3.5 billion Sin-
gaporean dollars on this initiative,
and Biopolis will be but one piece of
a 200 hectare biomedical develop-
ment called ‘‘One North.’’
Stem cell science has always been
a major part of this initiative, said Lee
Eng Hin, a professor of orthopedic
surgery at the National University of
Singapore and cochairman of the Sin-
gapore Stem Cell Consortium (SSCC).
Singapore’s affinity with stem cells, af-
ter all, ‘‘goes way back in time,’’ Lee
observed. In 1993, Ariff Bongso, a Sri
Lankan-born fertility specialist working
at the university’s hospital, had a vision
that the magazine Asiaweek described
as ‘‘a whisper from God’’ when he
grasped the potential medical useful-
ness of cells from IVF embryos. He
went on to isolate them, although he
was unable to sustain their growth
in vitro beyond two passages.
Biopolis, a broad and busy spec-
trum of largely government-funded
stem cell research—everything from
ES to adult cells, basic to clinical—is
clear indication of a small nation eager
to stay at the forefront. Biopolis
houses seven research institutes man-
aged by A*STAR, the Agency for Sci-
ence, Technology and Research, five248 Cell Stem Cell 1, September 2007 ªof which are heavily involved in stem
cells: the Genome Institute of Singa-
pore (GIS), the BioInformatics Institute
(BII), the Institute of Molecular and Cell
Biology (IMCB), the Bioprocessing
Technology Institute (BTI), and the
Institute of Medical Biology (IMB).
Researchers at the Institute of Bio-
engineering & Nanotechnology (IBN)
also handle stem cells, but to a lesser
degree. So far, the only company of
the two dozen or so firms located at
Biopolis to focus on stem cells is ES
Cell International (ESI).
‘‘Biopolis constitutes a fantastic
research environment,’’ said ESI’s for-
mer chief executive Alan Colman. As of
July 1, Colman, who is known inter-
nationally for helping the Roslin Insti-
tute to clone Dolly, moved from Helios
to the Proteos building at Biopolis to
become the executive director of
the Singapore Stem Cell Consortium.
‘‘One of the attractive aspects of Biop-
olis is that it’s the way a small island
can artificially create critical mass,’’
he noted. ‘‘It takes the view that there’s
no way it can sustain the number and
quality of scientists that you’ll find in
a Boston, or certain other hot areas in
North America. But what you can do
is bring everyone together as close
as possible so that you can maximize
the benefit of your resources.’’
And vast resources Biopolis does
have, particularly in the form of people
and funding. There are the many dis-
tinguished senior scientists from the
stem cell and related fields that Philip
Yeo lured from other continents, earn-
ing him the moniker of ‘‘serial kidnap-
per.’’ There is also local talent, like
stem cell researcher Huck-Hui Ng,
who might have emigrated had Biopo-
lis not been built. The hope is to boost
the local pool to 1000 PhDs by 2015 by
way of a national science scholarships
program that began in 2001.
Kidnapped husband-wife teams in-
clude David Lane, of p53-gene fame,
who directs the IMCB institute and
is the new chair of the Biomedical
Research Council, and Birgitte Lane,
who coordinates the study of epithelial2007 Elsevier Inc.stem cells at IMB; UCSD scientists Ed-
ward Holmes and Judith Swain were
recruited to guide Biopolis’s trans-
lational medical research; and Neal
Copeland and Nancy Jenkins from
the National Cancer Institute. Another
NCI scientist enticed to Biopolis, Edi-
son Liu, who oversees GIS, in turn re-
cruited hematologist Bing Lim from
Harvard Medical School.
Alan Colman came to stay in 2002,
when he joined ES Cell International’s
Singapore office as its first full-time
employee. The company, which fo-
cuses entirely on human embryonic
stem cells, moved to Biopolis a year
later. ESI at the time was based in Aus-
tralia, even though it was a Singapore-
registered company. Colman recog-
nized that Singapore, not Australia,
presented a brighter future in terms
of financing. In Singapore, the attitude
toward startups was different, he said.
‘‘Yes, there was a desire to make
money, but Singapore’s decision
makers also wanted to increase the
sophistication of the work force and
bring in people who could mentor the
local talent,’’ he recounted. ‘‘This dou-
ble-objective meant there was going
to be more of a secure source of fi-
nancing, at least in the short term,
than in Australia.’’
ESI moved entirely to Biopolis in
2004. The majority of its financing has
come from the Singapore government,
directly or indirectly, according to Col-
man, who remains on the company’s
board. ‘‘We would have been dead in
the water in the US or UK, because
for a private stem cell company, it’s
very tough to raise money,’’ he said.
It’s hard for a stem cell company to
be profitable within the time frame
that investors would like to see a re-
turn. This is one reason, he said,
that ESI is downsizing its R&D in
cell therapies for heart disease and
diabetes and upsizing ‘‘more near-
market opportunities,’’ like making
and selling cardiac cells for drug
toxicity studies.
Funds available for Biopolis re-
searchers flow from primarily two
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itsownbudget, itsemployeesessentially
paid by A*STAR. A researcher can also
receive funds from the Singapore Stem
Cell Consortium, which came into exis-
tence in 2005 expressly to coordinate
Singapore’s stem cell community and
nourish it with grant funds. Its support
is also government based, because
SSCC is under the auspices of the Bio-
medical Research Council. Last year,
SSCC gave out about $10 million in
grants, according to Lee.
Bing Lim, the Senior Group Leader
for the Genome Institute’s Stem Cell
and Development Biology Group, ap-
preciates the speed of his institute’s
intramural funding system. ‘‘If some-
thing is hot, we can make our own in-
ternal decisions and fund it straight
away,’’ he described. After a grant pro-
posal is submitted, a meeting of the
review committee can be convened
in a few days, and, if approved, fund-
ing can start almost immediately, he
said, whereas ‘‘at the NIH, it can take
6–8 months after submitting a grant
proposal before you get any funds, if
you are successful.’’
There’s a lot about Biopolis’s physi-
cal location that can encourage collab-
orations. It has its own academic and
corporate epicenter, it is located a
few minutes from researchers at the
National University and Hospital, and
it’s smack in the center of one of Asia’s
Figure 1. Singapore’s Biopolis
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ment is very open for collaborations,’’
said Ian McNiece, who recently joined
the Stem Cell Institute at the University
of Miami. During the two years he ran
Johns Hopkins’ research division at
Biopolis, ‘‘People were very eager to
discuss collaborative projects, and
we were in the midst of setting some
exciting ones up, which added to the
disappointment of having to leave.’’
A*STAR terminated its relationship
with the Hopkins’ Singapore division
in the summer of 2006, having spent
more than $50 million on the venture.
It alleged that Hopkins hadn’t accom-
plished certain milestone markers.
Others have remarked that Bio-
polis’s collaborations between aca-
demics and industry could be stronger
and that the A*STAR institutes act
more like corporate silos than the edu-
cational entities they strive to be. Be-
cause the stem cell work taking place
at Biopolis is raw R&D, with no prod-
ucts yet being manufactured, to what
extent the A*STAR institutes can per-
petuate entrepreneurial ties, whether
with groups close by or far away, re-
mains to be seen.
‘‘It’s never easy in any environment
to develop working relationships either
with other companies or other aca-
demics,’’ Colman noted. ‘‘There are
sensitivities about data, privacy, intel-
lectual property—in any relationship,
in any country—and Singapore is no
different. Here, because of everyone
being close together, it’s easier to con-
ceive of and plan for collaborations.
But actually getting it all formalized
can take longer than you want.’’
Controls on human embryonic stem
cell use are similar to those in the
United Kingdom, with stipulations
like the 14 day cutoff and no reproduc-
tive cloning. There’s this difference,
however, said Colman: In Singapore,
the controls aren’t legislated; they
are guidelines. ‘‘But Singapore has a
reputation for authoritarianism, and
guidelines have the impact of laws,’’
he said.
The view from outside, that Singa-
pore’s regulations are lenient, ‘‘is a
misconception in my opinion,’’ says
Ian McNiece. In his experience, ‘‘a lot
of uses of human cells were overregu-
lated compared to regulations in theSeptember 2007 ª2007 Elsevier Inc. 249
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ProfileUS,’’ he said, and gave this example.
‘‘To purchase existing human cell lines
from ATTC for laboratory studies, you
needed formal IRB approval, which
isn’t done in the States. It wasn’t
hard to get, but it was time consuming,
costly, and bureaucratic.’’
To move beyond basic research, Bi-
opolis researchers are girding up the
staff and infrastructure for translational
research. The SSCC, for instance, has
given the Bioprocessing Technology
Institute the task of building a GMP-250 Cell Stem Cell 1, September 2007 ª2grade facility for the expansion of cells
for therapies. ‘‘We’re aiming for the
facility to be functional by mid 2008,’’
said Andre Choo, BTI Senior Scientist
in human ES cells.
Bing Lim, who began coming over
on a part-time basis in 2002 due to
Ed Liu’s invitation to help launch
GIS’s stem cell program, now spends
most of his time at Biopolis. He feels
at home in Singapore, having been
born in neighboring Malaysia, plus
there are many things about Biopolis007 Elsevier Inc.that he really likes—the mesh of biol-
ogy and technology, the highly moti-
vated students he is training, and the
collaborative spirit.
At Harvard Medical School, ‘‘You
are one person out of hundreds in an
academic center that has achieved
its pinnacle,’’ he remarked. ‘‘You feel
you wouldn’t be missed. In Singapore,
you see a country that is striving to
build a center of excellence and con-
stantly raising its own bar, and you
know your contribution can matter.’’
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